Inhibitor Therapeutics, Inc. (INTI)

Inhibitor Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	2.14	2.02	0.65	0.32	0.87	1.54
Research & Development	1.42	1.38	0.01	0	0.19	1.21
Operating Expenses	3.55	3.4	0.66	0.33	1.06	2.75
Operating Income	-3.55	-3.4	-0.66	-0.33	-1.06	-2.75
Interest Income	0.38	0.38	0	0	0	0.01
Interest Expense	0.09	0	0.02	0.01	0	0
Other Expense / Income	0.69	0	-12.84	-0.04	-	-
Pretax Income	-3.17	-3.03	12.16	-0.3	-1.06	-2.73
Income Tax	-0.78	-0	0.06	0.01	-0	-0.01
Net Income	-3.17	-3.03	12.11	-0.31	-1.06	-2.72
Shares Outstanding (Basic)	172	172	366	376	372	370
Shares Outstanding (Diluted)	172	172	368	376	372	370
Shares Change	0.17%	-53.25%	-2.25%	1.16%	0.40%	0.17%
EPS (Basic)	-0.02	-0.02	0.03	-0.00	-0.00	-0.01
EPS (Diluted)	-0.02	-0.02	0.03	-0.00	-0.00	-0.01
Free Cash Flow	-3.1	-2.7	11.74	-0.22	-0.83	-2.71
Free Cash Flow Per Share	-0.02	-0.02	0.03	-0.00	-0.00	-0.01
Effective Tax Rate	-	-	0.45%	-	-	-
EBITDA	-3.37	-3.4	-0.66	-0.33	-1.06	-2.75

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.